Clinical trials: Liver Cell Carcinoma
Primary Liver Cancer, Hepatocellular Carcinoma
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
- Conditions
- Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma
- Trial name
- NCT05292443
- Testing
- Observation
- Where
- 5 sites in China
- Sponsor
- Geneplus-Beijing Co. Ltd.
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
- Trial name
- TREMENDOUS-2 (NCT07081633)
- Testing
- Durvalumab, Tremelimumab, Lenvatinib
- Where
- 23 sites in China, Hong Kong
- Volunteers
- 114 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma
- Trial name
- NCT00423306
- Testing
- Darinaparsin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Alaunos Therapeutics
Hepatocellular Carcinoma
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
This study is an open phase II clinical study, which consists of part a and Part B. Part a will evaluate the safety and tolerability of absk-011 combined with atilizumab in patients with advanced or unresectable HCC to And pk/pd…
- Trial name
- NCT05441475
- Testing
- ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w, ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg, ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Hepato Cellular Carcinoma (HCC)
First Line Hepato Cellular Carcinoma (HCC)
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
- Trial name
- BRISK FL (NCT00858871)
- Testing
- Brivanib, Sorafenib
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,714 people
- Sponsor
- Bristol-Myers Squibb
Liver Tumor, Hepatocellular Carcinoma
NeuWave Microwave Ablation HCC China Study
This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the…
- Trial name
- NW (NCT03783871)
- Testing
- Microwave ablation
- Where
- 4 sites in China
- Volunteers
- 135 people
- Sponsor
- Ethicon, Inc.
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Hepatocellular Carcinoma
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.
- Trial name
- HCC (NCT04560894)
- Testing
- SCT-I10A, SCT510, Sorafenib 200mg
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Sinocelltech Ltd.
Hepatocellular Carcinoma
Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard…
- Trial name
- NCT05072041
- Testing
- Nexsphere™
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Next Biomedical Co., Ltd.
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Hepatocellular Carcinoma
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
- Trial name
- NCT07813572
- Testing
- ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Unresectable Hepatocellular Carcinoma
First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
This study looks at how a combination of two medicines, nivolumab and ipilimumab, is used to treat people with advanced liver cancer that cannot be removed by surgery.
- Trial name
- NCT07679061
- Testing
- Nivolumab plus ipilimumab
- Where
- 2 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Carcinoma, Hepatocellular
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT00108953
- Testing
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 96 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
The purpose of this research study is to determine whether JX-594 (Pexa-Vec) has significant anti-tumoral activity and tolerability in primary hepatocellular carcinoma and to determine the dose to be used in further testing.
- Trial name
- NCT00554372
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Jennerex Biotherapeutics
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
Hepatocellular Carcinoma, Hepatocellular Carcinoma Surveillance
Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma…
- Trial name
- NCT03628651
- Testing
- Blood Sample Collection
- Where
- 74 sites in United States, France and 5 more
- Volunteers
- 2,150 people
- Sponsor
- Exact Sciences Corporation
Hepatocellular Carcinoma
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00976170
- Testing
- GC33(RO5137382), Sorafenib
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 42 people
- Sponsor
- Chugai Pharmaceutical
Carcinoma, Hepatocellular, Pancreatic Cancer Metastatic
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
The purpose of this study is to collect the date on the safety and potential effectiveness of CART cells combined with interventional therapy in patients with advanced liver malignancy.
- Conditions
- Carcinoma, Hepatocellular, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
- Trial name
- NCT02959151
- Testing
- CAR-T cell
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Hepatocellular Carcinoma, Gastric Cancer
Combination of TATE and PD-1 Inhibitor in Liver Cancer
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab).
- Trial name
- TATE-PD1 (NCT03259867)
- Testing
- Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Teclison Ltd.